Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer

Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer

The goal of this observational, retrospective, non interventional study is to learn about the efficacy of an Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer (TNBC).

The main question it aims to answer is :

- What is the efficacy of this kind of treatment, by evaluating the pathological complete response (PCR), that is to say, the percentage of patients where no tumor cells remained when they underwent surgery after neoadjuvant treatment.

The other points that will be evaluated are:

• The treatment regimen
• The epidemiological characteristics of the treated population
• The efficacy by relapse-free survival ; overall survival
• The tolerability and adverse effects

The standard treatment for localized TNBC (larger than 2 cm or with lymph node involvement) is neoadjuvant chemoimmunotherapy, which includes anthracyclines. However, in real-world practice, some patients have a contrindication to this treatment because they have received it previously, are too old, or have comorbidities, particularly cardiovascular disease. Currently, there is limited data on the modalities and efficacy of such treatment.

Inclusion Criteria:

• Patients over 18 years of age
• Patients being treated for localized triple-negative breast cancer, who received neoadjuvant chemotherapy with immunotherapy, without anthracycline
• Patients who have undergone surgery, with an available pathology report.

Exclusion Criteria:

• Patient refusal to allow data use
• Patient who has not undergone surgery
• Metastatic patients
• Patients who have received at least one anthracycline-based treatment cycle